ASCO Annual Meeting

Belantamab mafodotin in combination with other therapies shows promise for patients with multiple myeloma following the first relapse.

Recent data shows that telehealth is comparable to quality of life to in-person visits for patients with advanced non–small cell lung cancer.

Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent prostate cancer, while still improving progression-free survival.

The addition of retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo for patients with limited-stage small cell lung cancer, leading researchers to argue for a new standard of care in this setting.

Progression-free survival was numerically improved with pembrolizumab plus sacituzumab govitecan vs sacituzumab govitecan alone in patients with HR-positive, HER2-negative metastatic breast cancer.

Suresh Ramalingam, MD, principal investigator of the phase 3 LAURA trial, explains the study's evaluation of osimertinib in EGFR-mutated non-small cell lung cancer.

Abemaciclib plus fulvestrant improved PFS compared with fulvestrant alone in certain patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Tucidinostat plus R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2.

Cabazitaxel plus abiraterone showed improved survival results for patients with previously treated metastatic castration-resistant prostate cancer.

Inavolisib combined with palbociclib and fulvestrant improved results for patients with HER2-negative, hormone receptor–positive, PIK3CA-mutated advanced or metastatic breast cancer.

Adagrasib significantly improved responses among patients with KRASG12C-mutated locally advanced or metastatic non–small cell lung cancer.

A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer.

Protocol amendment with sacituzumab govitecan shows promising responses, but questions remain for the use of the therapy in patients with bladder cancer.

Results from the AURA trial show the survival benefits of cisplatin-based chemotherapy in combination with avelumab.

Improved results were seen with subcutaneous amivantamab vs its intravenous formulation in patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation.

The small molecule inhibitor selectively targeting HIF-2α DFF332 shows promising preliminary activity and favorable safety in patients with advanced clear cell renal carcinoma.

Combining encorafenib/binimetinib before nivolumab/ipilimumab did not improve progression-free survival in BRAF V600E/K+ metastatic melanoma.

Frontline amivantamab plus lazertinib reduced the risk of disease progression or death by 30% versus osimertinib in patients with high-risk EGFR-mutant non–small cell lung cancer.

Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.

Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.

A new brentuximab vedotin-containing regimen for classical Hodgkin lymphoma has been shown to be more tolerable and effective than the current standard.

Over 8 years, dabrafenib and trametinib showed improved survival vs placebo in stage III melanoma, but overall and melanoma-specific benefits were not statistically significant.

The highest efficacy was observed in CP-CML patients harboring a BCR::ABL1 T315I mutation who received ponatinib at 45 mg daily.

The latest data on the combination of pelabresib and ruxolitinib in myelofibrosis may provide the rationale for a paradigm shift.

Puneeth Indurlal, MD, MS, discusses the implications of assessing for patients' health-related social needs during the course of cancer treatment at the 2024 ASCO Annual Meeting.

Lorlatinib improved progression-free survival vs crizotinib when used as a treatment in patients ALK-positive non–small cell lung cancer.

Among patients with Ph-positive chronic phase chronic myeloid leukemia, asciminib demonstrated positive results, including a better major molecular response rate at 48 weeks vs investigator-selected TKIs.